Invitae Adds 11 Panels to Its Genetic Tests for Disease, Including Muscular Dystrophy

Invitae Adds 11 Panels to Its Genetic Tests for Disease, Including Muscular Dystrophy
0
(0)

Invitae, which specializes in genetic information, has expanded its neurology and cardiology test offerings by adding 11 new panels for genetic diseases. The company has also updated 17 of its neurology panels and eight of its cardiology panels based on recent discoveries in the field of genetics, including tests for muscular dystrophies.

With this expansion, Invitae will be able to provide quality information on genetic changes proven to affect a series of neurologic and cardiovascular disorders, with the results coming in the same three-week period as previously, the company said in a press release.

The new panels are available immediately for use at children’s hospitals, and by pediatricians and medical genetics professionals, for diagnosis and care.

Invitae’s areas of genetic testing now include:

Furthermore, updates to existing panels included:

Prices do not differ regardless of how many genes are required to be analyzed for an accurate diagnosis. For payers and institutions in contact with Invitae, prices can start at $950, depending on the requirements. For third-party payers, outside of Invitae’s network, prices per clinical area start at $1,500. For patients who  do not have third-party insurance coverage or who do not meet insurance criteria for coverage, Invitae’s offers full tests at $475 per clinical area.

“Invitae is steadfast in its commitment to making high-quality genetic tests based on the latest clinical and scientific evidence available to patients and their family members,” Robert Nussbaum, M.D., Invitae’s chief medical officer, said in the release. “The launch of our new and updated panels clearly illustrates our ongoing dedication to careful and comprehensive gene curation.”

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
×
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
Latest Posts
  • Hockey player Ryan Getzlaf
  • Sarepta partnership
  • MYO-101 for LGMD2E
  • ICER review

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?